Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
Surrozen (Nasdaq: SRZN) has published new data in eLife demonstrating the potential of its proprietary SWEETS platform to enhance Wnt signaling. The study highlights the development of two new ASGR-targeted SWEETS bispecific antibodies that improve Wnt-signal activation through a unique protein degradation platform. This innovation offers promising new avenues for treating liver diseases by promoting cell-specific regenerative therapeutics. Additionally, Surrozen released a review in iScience detailing advancements in Wnt-activating technologies, underscoring the significant progress in the field and its potential to address various tissue degenerative diseases.
- Publication in eLife enhances credibility and visibility.
- Two new ASGR-targeted SWEETS bispecific antibodies demonstrate improved Wnt-signal activation.
- Potential for new liver disease treatments through cell-specific regenerative therapeutics.
- Review article in iScience summarizes significant advancements in Wnt-activating technologies.
- Research highlights multiple mechanisms for enhancing Wnt signaling, broadening therapeutic options.
- No immediate clinical applications provided in the announcement.
- Lack of detailed financial data or revenue forecasts.
- Potential risks in translating preclinical results to human applications.
- information on commercialization timelines or partnership opportunities.
Insights
The publication of Surrozen's study in eLife highlights significant advancements in targeted protein degradation (TPD) technologies, specifically their SWEETS platform. The ability of these bispecific antibodies to enhance Wnt signaling in a cell-specific manner is noteworthy. Enhanced Wnt signaling is important for tissue repair and regeneration, offering promising therapeutic options for diseases like severe liver conditions.
In the study, new ASGR-targeted SWEETS bispecific antibodies demonstrated potent and specific signaling in hepatocytes, leading to improved liver function in mouse models. This specificity and efficacy indicate potential for developing new treatments that are more precise and effective compared to current options. The use of TPD platforms to enhance Wnt signaling is innovative, expanding the therapeutic landscape for regenerative medicine.
For retail investors, this foundational research suggests Surrozen is on the cutting edge of regenerative medicine, particularly for liver diseases. The validation of their technology through peer-reviewed publication adds credibility, which could positively impact investor confidence in the company's long-term prospects.
From a market perspective, the publication in eLife can be seen as a significant step for Surrozen. Peer-reviewed research publications often bolster a company's reputation and can be a precursor to increased investor interest and market valuation. This study not only validates the SWEETS platform but also demonstrates its unique capabilities in enhancing Wnt signaling, potentially opening new avenues for therapeutic applications.
However, it's important to recognize that while the findings are promising, they are still in early stages. The practical application and commercialization of these therapies will require extensive clinical trials and regulatory approvals, processes that are costly and time-consuming. Investors should weigh the potential long-term benefits against these challenges.
For the short-term, this publication might create positive sentiment around Surrozen's stock, potentially leading to a stock price increase. But investors should remain cautious and consider the long-term horizon when evaluating the company's true potential.
The SWEETS platform represents an intriguing technological advancement in the field of targeted protein degradation. By creating bispecific antibodies that can specifically enhance Wnt signaling in liver cells, Surrozen has developed a novel approach that could have far-reaching implications for regenerative medicine. The technology stands out due to its specificity and the innovative use of the ASGR receptor to target liver cells, which could lead to highly effective treatments with fewer side effects.
This development is particularly relevant in the context of treating severe liver diseases, where current therapeutic options are limited. The ability to activate Wnt signaling in a targeted manner could revolutionize treatment protocols, potentially leading to improved patient outcomes and reduced healthcare costs associated with liver diseases.
For investors, the technological innovation behind the SWEETS platform signifies a strong competitive advantage for Surrozen. This could translate to strategic partnerships, licensing opportunities and increased market share in the long term.
Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches
Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies
Results demonstrated that the two new ASGR-targeted SWEETS bispecific antibodies enhanced Wnt-signal activation through the unique TPD platform
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS (Surrozen Wnt signal Enhancer Engineered for Tissue Specificity) bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications (Click: HERE).
This publication presented research that was focused on extending previous work by Surrozen scientists on fusing an RSPO2** mutant protein to an antibody that binds ASGR1*** which led to hepatocyte (liver cell)-specific enhanced signaling, proliferation, and restored liver function in mouse models. In this publication, the authors described the development of two new ASGR bispecific antibodies which revealed distinct epitopes on both ASGR1 and ASGR2 that resulted in a robust and cell-specific Wnt-signal activation. These ASGR-targeted SWEETS molecules represent a unique targeted protein degradation (TPD) platform, that functions via multiple mechanisms, and expands the potential opportunities to treat liver diseases through cell or tissue-specific regenerative therapeutics with enhanced Wnt signal activation.
“This work published in eLIfe provides an important new approach to boost Wnt-signaling through protein degradation technologies and is an important demonstration of our continuing efforts as a company to enhance options available in areas of unmet therapeutic need including severe liver disease,” said Yang Li, Ph.D., Executive Vice President, Research at Surrozen.
Surrozen also announced the publication of a review article in iScience (Click: HERE). This review article provided a comprehensive summary of work done by both Surrozen scientists and other researchers in the field on the invention of various Wnt activating platforms. This review highlights the rationales and design rules described so far and the insights learned from the studies of these novel molecules on various tissues. This review highlights the exciting progress made in this emerging field and the potential of Wnt agonists in the treatment of numerous tissue degenerative diseases.
*TPD – Total protein degradation technologies focus on the complex networks of biochemical processes in protein homeostasis and includes removal of damaged proteins and targeted degradation of intracellular, extracellular, and cell-surface proteins with unwanted functions
**RSPO2 = R-spondin 2
***ASGR = asialoglycoprotein receptor
About SZN-043 for Severe Alcohol-Associated Hepatitis
SZN-043 is the first development candidate using Surrozen’s SWEETS™ technology. Surrozen is developing SZN-043 for severe liver diseases, initially focusing on severe alcohol-associated hepatitis. The Company has completed a Phase 1a clinical trial in patients with a history of liver cirrhosis and healthy volunteers. SZN-043 was safe and well tolerated in single or multiple IV doses and demonstrated evidence of target engagement, Wnt signal activation and effects on liver function.
The Phase 1b clinical trial in patients with severe alcohol-associated hepatitis began enrollment in the second quarter of 2024 and the Company expects that proof-of-concept data from this trial may be available in the first half of 2025.
About Wnt Signaling
Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including liver, intestine, lung, kidney, retina, central nervous system, cochlea, bone, and others. Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries. Surrozen’s platform and proprietary technologies have the potential to overcome the limitations in pursuing the Wnt pathway as a therapeutic strategy.
About Surrozen
Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. For more information, please visit www.surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidate SZN-043 (including anticipated clinical development plans and timelines, and the availability of data, the potential for such product candidate to be used to treat human disease, as well as the potential benefits of such product candidate), and the Company’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to SZN-043, SZN-413 and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for SZN-043, SZN-413, or other future product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2023 and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor and Media Contact:
Investorinfo@surrozen.com
FAQ
What did Surrozen announce on June 12, 2024?
What is the significance of Surrozen's SWEETS platform?
How do the new ASGR-targeted SWEETS bispecific antibodies work?
What is the potential impact of Surrozen's new data on SRZN stock?
Where can I find detailed information on Surrozen's research?
